science wire
« BACK
Pharmacology - Health - 01.04.2019
Health - Pharmacology - 01.04.2019
Pharmacology - Chemistry - 29.03.2019 
Raising smoking age and mapping HIV transmission: News from the College
Here's a batch of fresh news and announcements from across Imperial. From recommendations to raise the smoking age to 21, to sequencing HIV transmission networks in Africa, here is some quick-read news from across the College.
Life Sciences - Pharmacology - 28.03.2019
Pharmacology - Health - 28.03.2019
Pharmacology - Health - 27.03.2019
Health - Pharmacology - 26.03.2019
Pharmacology - Health - 25.03.2019 
Researchers aim to use gene therapy to treat hearing deafness
Professor Schambach was awarded approximately two million euros from the European Union for his "iHEAR" project / New gene therapies shall protect children and adults from hearing loss High accolades
Health - Pharmacology - 22.03.2019
Health - Pharmacology - 21.03.2019
Pharmacology - 20.03.2019
Health - Pharmacology - 20.03.2019
Pharmacology - Health - 19.03.2019
Health - Pharmacology - 15.03.2019 
Researchers offered ’quick and easy’ grants to get medical innovations started
A scheme is offering grants to help researchers test ideas for translating their research into new drugs, diagnostics or medical devices.
Pharmacology - Health - 15.03.2019
Health - Pharmacology - 14.03.2019
Pharmacology - 14.03.2019 
Drug use in Swiss cities unchanged
In a large-scale, Europe-wide drug monitoring project, the wastewater of around 38 million people in 85 cities was analysed in the spring.
Pharmacology - Social Sciences - 14.03.2019
Pharmacology - Health - 14.03.2019
Pharmacology - Business / Economics - 13.03.2019
Health - Pharmacology - 13.03.2019 
Reducing the burden of tuberculosis treatment
Drug delivery system would allow patients to switch from daily to monthly doses. One-third of the world's population is infected with TB, and more than 1 million people die from the disease every year.
Health - Pharmacology - 12.03.2019
Health - Pharmacology - 11.03.2019
Health - Pharmacology - 11.03.2019
Health - Pharmacology - 11.03.2019
Pharmacology - Life Sciences - 08.03.2019 
Safer brains and mechanical hearts: News from the College
Here's a batch of fresh news and announcements from across Imperial. From better materials for crash helmets, to a bioreactor which mimics heartbeats, here is some quick-read news from across the College.
Pharmacology - Health - 08.03.2019
Health - Pharmacology - 07.03.2019
Pharmacology - Health - 07.03.2019
Health - Pharmacology - 05.03.2019
Health - Pharmacology - 28.02.2019
Health - Pharmacology - 28.02.2019
Pharmacology - Health - 27.02.2019
Pharmacology - Health - 27.02.2019
Health - Pharmacology - 25.02.2019
Health - Pharmacology - 25.02.2019
Pharmacology - Health - 20.02.2019
Pharmacology - Health - 19.02.2019
Health - Pharmacology - 19.02.2019
Pharmacology - 18.02.2019 
Testing pain relief treatments for whiplash
Researchers are investigating the effectiveness of non-opioid pain relief for people with acute whiplash.
Health - Pharmacology - 13.02.2019
Pharmacology - Business / Economics - 13.02.2019 
Redesigning pharmacies with the consumer in mind
Alto Pharmacy uses software and an innovative operations model to improve access to medication. Getting medication to a patient requires coordination between the doctor who writes the prescription, the insurance company that provides coverage, and the pharmacy that ultimately hands over the drug.
Health - Pharmacology - 12.02.2019
Pharmacology - 12.02.2019
Health - Pharmacology - 11.02.2019 
New children’s research facility opens at Imperial
A research facility that aims to improve the quality of life, treatment and care for children with complex diseases formally opened this month.
Health - Pharmacology - 07.02.2019
Pharmacology - Health - 07.02.2019
Life Sciences - Pharmacology - 07.02.2019 
This is a Neuron on Nicotine
When a person takes a puff on a cigarette, nicotine floods into the brain, latching onto receptors on the surface of neurons and producing feelings of happiness.
Pharmacology - Health - 06.02.2019
Health - Pharmacology - 05.02.2019
Pharmacology
Results 101 - 150 of 1314.
Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alter
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alter
Here's a batch of fresh news and announcements from across Imperial. From recommendations to raise the smoking age to 21, to sequencing HIV transmission networks in Africa, here is some quick-read news from across the College.
Should more medications be available over the counter?
Making more drugs available 'over the counter' would be a win for the public and the health care system write University of Sydney pharmacy experts.
Making more drugs available 'over the counter' would be a win for the public and the health care system write University of Sydney pharmacy experts.
Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years Up to 80% of patients with relaps
Mayzent (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years Up to 80% of patients with relaps
Personalized in vitro model enables drug screening for kidney cancer
One way to treat the most common type of kidney cancer is to use anti-angiogenic drugs to cut off the blood supply to the tumors, but patients respond differently to the drugs, and choosing the wrong one can make the cancer grow faster.
One way to treat the most common type of kidney cancer is to use anti-angiogenic drugs to cut off the blood supply to the tumors, but patients respond differently to the drugs, and choosing the wrong one can make the cancer grow faster.
Professor Schambach was awarded approximately two million euros from the European Union for his "iHEAR" project / New gene therapies shall protect children and adults from hearing loss High accolades
Bringing a new generation of drugs to patients
Cardiff University is stepping up the development of new drugs for mental health and central nervous system conditions, with the launch of the Medicines Discovery Institute. Focusing on areas of unmet clinical need, the new institute will develop novel medications to improve the lives of people across the world.
Cardiff University is stepping up the development of new drugs for mental health and central nervous system conditions, with the launch of the Medicines Discovery Institute. Focusing on areas of unmet clinical need, the new institute will develop novel medications to improve the lives of people across the world.
Researchers awarded $40 million to study opioid addiction treatments
Yale School of Medicine faculty have been awarded $40 million in grants to study medication treatment for veterans with opioid addiction.
Yale School of Medicine faculty have been awarded $40 million in grants to study medication treatment for veterans with opioid addiction.
Ground breaking pancreatic cancer trial reaches patient milestone
A ground breaking pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumours, has successfully recruited its 100th patient.
A ground breaking pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumours, has successfully recruited its 100th patient.
FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC
A scheme is offering grants to help researchers test ideas for translating their research into new drugs, diagnostics or medical devices.
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 C
In a large-scale, Europe-wide drug monitoring project, the wastewater of around 38 million people in 85 cities was analysed in the spring.
European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously
Drug delivery system would allow patients to switch from daily to monthly doses. One-third of the world's population is infected with TB, and more than 1 million people die from the disease every year.
Evidence-based web tool aims to better inform and refine need for treatment in early prostate cancer
A new tool to predict an individual's prognosis following a prostate cancer diagnosis could help prevent unnecessary treatment and related side effects, say researchers at the University of Cambridge. We believe this tool could significantly reduce the number of unnecessary - and potentially harmful - treatments that patients receive and save the NHS millions every year Vincent Gnanapragasam The tool, PREDICT Prostate, launches today to coincide with publication in the journal PLOS Medicine of the research that underpins it.
A new tool to predict an individual's prognosis following a prostate cancer diagnosis could help prevent unnecessary treatment and related side effects, say researchers at the University of Cambridge. We believe this tool could significantly reduce the number of unnecessary - and potentially harmful - treatments that patients receive and save the NHS millions every year Vincent Gnanapragasam The tool, PREDICT Prostate, launches today to coincide with publication in the journal PLOS Medicine of the research that underpins it.
FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ
Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag
Here's a batch of fresh news and announcements from across Imperial. From better materials for crash helmets, to a bioreactor which mimics heartbeats, here is some quick-read news from across the College.
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara *
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Oxford-Harrington Rare Disease Centre to research rare diseases therapies
The University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases.
The University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases.
Yeast produce low-cost, high-quality cannabinoids
UC Berkeley synthetic biologists have engineered brewer's yeast to produce marijuana's main ingredients-mind-altering THC and non-psychoactive CBD-as well as novel cannabinoids not found in the plant itself.
UC Berkeley synthetic biologists have engineered brewer's yeast to produce marijuana's main ingredients-mind-altering THC and non-psychoactive CBD-as well as novel cannabinoids not found in the plant itself.
Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
FDA grants Priority Review to Roche’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
Researchers are investigating the effectiveness of non-opioid pain relief for people with acute whiplash.
Novartis receives FDA approval for Egaten for the treatment of fascioliasis, a neglected tropical disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infes
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver fluke infes
Alto Pharmacy uses software and an innovative operations model to improve access to medication. Getting medication to a patient requires coordination between the doctor who writes the prescription, the insurance company that provides coverage, and the pharmacy that ultimately hands over the drug.
£1.5m funding boost for UofG diagnostics spinout
A University of Glasgow spinout which is bringing to market a fast, affordable and efficient new way to diagnose diseases has received a major funding boost.
A University of Glasgow spinout which is bringing to market a fast, affordable and efficient new way to diagnose diseases has received a major funding boost.
GPs and pharmacists don’t have time to involve patients in medication reviews
GPs and pharmacists struggle to find the time to involve patients in medication reviews, despite National Institute for Health and Care Excellence (NICE) guidance advising them to do so, according to a study by researchers at the University of Bristol's Centre for Academic Primary Care.
GPs and pharmacists struggle to find the time to involve patients in medication reviews, despite National Institute for Health and Care Excellence (NICE) guidance advising them to do so, according to a study by researchers at the University of Bristol's Centre for Academic Primary Care.
A research facility that aims to improve the quality of life, treatment and care for children with complex diseases formally opened this month.
In seminar, Tom Lynch talks drug development and improving patient outcomes
New Haven, CT - Dr. Tom Lynch, former Director of Yale Cancer Center and current Chief Scientific Officer at Bristol-Myers Squibb, returned to campus Wednesday to deliver a talk on 'Cancer Drug Discovery: Role of the University/Hospital, Biotech and Pharma to Improve Patient Outcomes.
New Haven, CT - Dr. Tom Lynch, former Director of Yale Cancer Center and current Chief Scientific Officer at Bristol-Myers Squibb, returned to campus Wednesday to deliver a talk on 'Cancer Drug Discovery: Role of the University/Hospital, Biotech and Pharma to Improve Patient Outcomes.
Teaching the immune system to fight cancer
Editor's note: This piece was adapted from a story that originally appeared in the University of Chicago Magazine.
Editor's note: This piece was adapted from a story that originally appeared in the University of Chicago Magazine.
When a person takes a puff on a cigarette, nicotine floods into the brain, latching onto receptors on the surface of neurons and producing feelings of happiness.
